
July 11 (Reuters) - EMA:
EMA CONCLUDES REVIEW OF SEMAGLUTIDE MEDICINES AND STARTS REVIEW OF TWO CHICKENPOX VACCINES
IXCHIQ TEMPORARY RESTRICTION ON VACCINATING PEOPLE 65 YEARS AND OLDER TO BE LIFTED
PRAC CONCLUDED IXCHIQ SHOULD ONLY BE GIVEN WHEN THERE IS A SIGNIFICANT RISK OF CHIKUNGUNYA INFECTION & AFTER CONSIDERATION OF BENEFITS & RISKS
PRAC RECOMMENDED UPDATE TO PRODUCT INFORMATION OF VARILRIX AND VARIVAX TO FURTHER DESCRIBE SEVERITY OF RISK OF ENCEPHALITIS
AMENDED PRODUCT INFORMATION OF CHICKENPOX VACCINES WILL GIVE FURTHER DETAIL ON THE KNOWN SIDE EFFECT ENCEPHALITIS
PRAC ASSESSING NEW DATA ON POTENTIAL RISK OF NEURODEVELOPMENTAL DISORDERS IN CHILDREN BORN TO MEN TREATED WITH VALPROATE